|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||3.15 / 10.73|
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aratana Therapeutics, Inc securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the "Class Period") of the important April...
We answer recent reader questions about three of the biotech stocks we regularly cover.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aratana Therapeutics, Inc.
Goldberg Law PC announces that it is investigating Aratana Therapeutics, Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Aratana Therapeutics, Inc securities (NASDAQ: PETX) from March 16, 2015 through February 3, 2017,...
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Aratana Therapeutics, Inc.
Stocks close out Monday lower as uncertainty over potential policy moves from Donald Trump's administration continue to weigh on Wall Street.
Stocks fall Monday as uncertainty over potential policy moves from Donald Trump's administration weigh on Wall Street.
Market is showing a lack of interest today.
Levi & Korsinsky announces it has commenced an investigation of Aratana Therapeutics, Inc.
Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.
Provides Update on Availability of ENTYCE® (capromorelin oral solution)
Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.
This morning the most notable aspect of the action is the complete failure to bounce so far.
Elanco launches first-in-class piprant for veterinary use
Animal health and oncology deal activity is heating up in 2017.
With poor breadth and money managers hiding in large-caps, I am being cautious, right now.
M&A activity should perk up substantially in the small and mid-cap space this year.
If the indices take out yesterday's lows I'll be very bearish very quickly.
This biopharma company's Relistor drug should send revenues sharply higher this year.
I've got my eye on steel and biotechnology names to put cash to work.